Form 4: Lantern Pharma CEO Panna Sharma Acquires 70,000 Stock Options

Lantern Pharma's CEO, Panna Sharma, reports the acquisition of 70,000 stock options exercisable over a 24-month period.

Summary

• On July 15, 2024, Panna Sharma, the President and CEO of Lantern Pharma Inc., acquired 70,000 stock options.
• These options are granted under the company's Amended and Restated 2018 Stock Incentive Plan.
• The exercise price of each option is $4.35.
• The options will vest and become exercisable in equal monthly increments over a 24-month period, starting August 15, 2024.
• The options expire on July 15, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.

Industry Context

This is a standard practice for incentivizing executives in publicly traded companies, particularly in the biotech industry where long-term growth is crucial.

Comparison to Industry Standards

• Granting stock options to executives is a common practice in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Biogen also use stock options as part of their executive compensation packages.
• The vesting schedule and exercise price are typical for such grants, aligning executive incentives with long-term shareholder value.

Stakeholder Impact

• Shareholders may view this as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see this as a sign of confidence in the company's future.

Key Dates